Jan, 2007

U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces European Regulatory Approval of Tarceva(R) for Treatment of Patients with Pancreatic Cancer
MELVILLE, N.Y.--(BUSINESS WIRE)--Jan. 29, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche, its international partner for Tarceva® (erlotinib), announced today that the European...
Read More
U.S.A.
News / Therapeutic Area News
Astellas Pharma US, Inc. Announces Availability of MYCAMINE® 100mg Vial
Astellas Pharma US, Inc. announced today the availability of their antifungal agent MYCAMINE® (micafungin sodium) for injection in a 100mg vial format. Approved in 2005 for the treatment of...
Read More

Dec, 2006

U.S.A.
News / Therapeutic Area News
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE®
Astellas Pharma US, Inc. announced today that, on December 21, 2006, they submitted a Supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) seeking approval for the...
Read More

Nov, 2006

U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces That Tarceva(R) Received Positive Opinion from Health Authorities in European Union for the Treatment of Patients with Pancreatic Cancer
MELVILLE, N.Y.--(BUSINESS WIRE)--Dec. 15, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche, its international partner for Tarceva® (erlotinib), announced today that the European Committee...
Read More

Oct, 2006

U.S.A.
News / Therapeutic Area News
Astellas Pharma US, Inc., GlaxoSmithKline, and VESIcare® (solifenacin succinate) Sponsor the #18 Race Car at Atlanta Motor Speedway to Raise Awareness about Overactive Bladder
Atlanta, GA (October 29, 2006) — It is estimated that 17 million men and women in the United States, especially those age 50 and older, may have a common yet under-recognized medical condition,...
Read More